ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1492 National Cancer Institute Html en Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version For acute lymphoblastic leukemia (ALL), the 5-year survival rate rose from 60% to about 90% for children younger than 15 years and from 28% to about 75% for adolescents aged 15–19 years between 1975 and 2010. Get information about risk factors, signs, diagnosis, genomics, survival, risk-based treatment assignment, and induction and postinduction therapy for children and adolescents with newly diagnosed and recurrent ALL.
prognostic factors0.457078
B-Cell Acute Lymphoblastic0.477707
Cancer Statistics Review0.442138
B-acute lymphoblastic leukemia0.487736
Leukemia Group0.457445
children0.485859
childhood lymphoblastic leukaemia0.461366
acute lymphoblastic leukaemia0.619966
acute lymphoblastic leukemias0.490719
leukemia cells.0.443609
prognostic significance0.464566
Nat Genet0.45804
leukemia susceptibility gene0.452718
Hyperdiploid leukemia cells0.447496
et al.0.591777
SEER Cancer Statistics0.449829
lymphoblastic leukemia consortium0.485454
childhood acute leukemias0.444646
frank leukemia0.449613
Br J Haematol0.473302
early T-cell precursor0.46793
PUBMED Abstract0.469887
concordant leukemia0.449352
residual leukemia0.447727
Pediatr Blood Cancer0.49042
acute lymphocytic leukemia0.489397
Leukemia Study Group0.454229
National Cancer Institute0.475056
acute lymphoblastic leukaemias0.494907
childhood leukemia0.453157
outcome0.442439
myeloid leukemia stem0.447271
lymphoblastic leukemia risk0.49811
lymphoblastic leukaemia aetiology0.462653
childhood0.471724
Abstract0.585405
Acute leukaemia0.444978
cancer group0.443895
Pediatr Hematol Oncol0.438989
Clin Oncol0.520227
Pediatric Oncology Group0.440216
infant leukemia0.443122
acute promyelocytic leukemia0.469574
acute lymphoblastic leukemia0.925289
acute leukemia0.478163
Lymphoblastic Leukemia Treated0.486039
Children Leukemia Group0.457299
leukemia cells0.45331
oncology group0.497434
CLICK HERE
1536 National Cancer Institute Html en Laetrile/Amygdalin (PDQ®)–Health Professional Version Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer.
cancer treatment0.52441
cancer cell inhibitors.0.542345
intravenous amygdalin treatment0.677872
amygdalin occurs0.621015
potential anticancer activity0.529695
cyanide poisoning0.73495
blood cyanide levels0.657623
intestinal bacteria0.607185
primordial germ cells0.521102
purported anticancer activity0.532782
oral amygdalin0.650441
cancer patients0.590892
complete responses0.526167
high-dose vitamin supplements0.5155
metabolic therapy0.516142
U.S.-patented Laetrile0.757295
laetrile therapy0.736124
amygdalin interacts0.616968
laetrile’s breakdown0.71917
laetrile practitioners.0.705315
anticancer activity0.587095
nontoxic intravenous form0.531127
specific anticancer properties0.534462
intravenous Laetrile0.740226
United States0.629681
positive results0.563482
case series0.523576
cancer cells0.637689
oral maintenance therapy0.601513
colon cancer cells0.550218
promising cancer therapies0.544057
term laetrile0.84507
human breast cancer0.525831
laetrile treatment.0.765844
higher-dose amygdalin therapy0.65865
National Cancer Institute0.610445
cyanide anion0.594345
partial responses0.519394
Laetrile supporters0.777243
term vitamin B-170.520783
amygdalin0.757648
enzyme beta-glucosidase0.562945
anticancer agent0.587895
case reports0.550533
hydrogen cyanide0.876372
cyanide group0.578561
laetrile0.994496
chemical amygdalin0.642935
cancer0.720035
CLICK HERE
1548 National Cancer Institute Html en Breast Cancer Screening (PDQ®)–Patient Version Mammogram, clinical breast exam (CBE), and MRI (magnetic resonance imaging) tests are used to screen for breast cancer. Learn about this and other tests that have been studied to detect or screen for breast cancer in this expert-reviewed summary.
cancer screening methods0.42533
fast-growing breast cancer0.440825
ongoing clinical trials0.389452
following PDQ summaries0.382952
PDQ cancer information0.474492
following PDQ summary0.39258
breast fluid0.391775
common screening test0.39988
routine breast cancer0.436027
clinical trials0.527662
cancer information summary0.430839
breast tissue sampling0.438767
breast cancer prevention0.479726
test results0.400913
test0.410305
Yearly MRI screening0.382239
NCI PDQ cancer0.406053
women0.476763
PDQ Screening0.392324
stage breast cancer0.437499
screening tests0.377685
breast cancer diagnosis0.443317
clinical breast exams0.420114
regular breast0.389266
Cancer Information Service0.377203
breast cancers0.414043
denser breast tissue0.419753
breast duct0.396464
breast tissue0.495937
Prevention Editorial Board0.379673
annual screening mammogram0.410065
National Cancer Institute0.431327
Cancer Screening Overview0.412144
breast cancer benefit0.435864
breast biopsy result0.412172
lymph vessels0.375923
breast tumors0.395991
breast cancer screening0.602061
Cancer screening trials0.429799
clinical breast exam0.420394
breast cancer0.970368
clinical breast0.421091
dense breast tissue0.418481
PDQ summary0.443066
false-positive screening mammogram0.452332
breast self-exams0.40904
cancer information summaries0.380757
comprehensive cancer information0.380439
screening mammogram0.469345
CLICK HERE
1565 National Cancer Institute Html null Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of lip and oral cavity cancer.
CLICK HERE
1595 National Cancer Institute Html en Gastric Cancer Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of gastric cancer.
treatment0.591238
cancer treatment0.450405
gastric cancer cells0.441573
Gastric Cancer Treatment0.444726
NCI-supported cancer0.4391
stomach0.735063
cancer cells0.582767
malignant tumor cells0.419107
body0.442061
Cancer Information Service0.403362
PDQ cancer information0.496418
specific cancer cells0.40594
HER2-positive gastric cancer0.441612
clinical trial search0.508645
stomach wall0.679257
treatment clinical trials0.435225
National Cancer Institute0.459181
clinical trials0.857251
nearby lymph nodes0.422969
cancer information summary0.459638
clinical trial0.69582
gastric cancer spreads0.435883
new treatment0.430993
gastric cancer0.961916
recurrent gastric cancer0.423214
) layer.0.427318
stomach disease0.413534
patients0.40139
metastatic gastric cancer0.437702
Stomach pain0.405557
NCI PDQ cancer0.415126
cancer clinical trials0.531962
lymph nodes0.644979
stage0.470953
stomach cancer0.464876
tumor0.483246
chemoradiation therapy0.469475
radiation therapy0.455319
Treatment Editorial Board0.403905
cancer information summaries0.401354
stomach discomfort0.411852
information0.507295
small intestine0.476652
subtotal gastrectomy0.452908
monoclonal antibody0.404834
General information0.405606
CLICK HERE
1753 National Cancer Institute Html en Hormone Therapy for Breast Cancer A fact sheet that describes types of hormone therapy, its role in preventing and treating breast cancer, and possible side effects.
Surgical Adjuvant Breast0.492707
estrogen0.502159
primary breast cancer0.489122
early-stage ER-positive breast0.480551
aromatase inhibitors anastrozole0.480936
ER-positive early-stage breast0.480383
aromatase inhibitors0.525562
breast cancer subtypes0.491642
metastatic ER-positive breast0.481109
early-stage breast cancer0.616245
tamoxifen0.550216
breast cancer hormone0.522198
ER-positive breast cancer0.553345
breast cancer prevention0.522495
breast cancer patients0.511592
postmenopausal breast cancer0.509489
new breast cancer0.500245
adjuvant hormone therapy0.504935
estrogen receptors0.483294
HR-positive breast cancer0.521679
hormone receptor-positive breast0.501962
metastatic breast cancer0.52726
invasive breast cancer0.511911
early breast cancer0.587772
breast cancer cells0.575964
breast cancer recurrence0.50934
breast cancers0.514423
ER-positive breast cancers0.488424
premenopausal women0.499525
National Cancer Institute0.500748
IBIS-I breast cancer0.488534
hormone therapy0.718328
hormone-sensitive breast cancer0.587411
breast tumors0.505842
postmenopausal women0.702436
breast cancer risk0.498557
International Breast Cancer0.496186
Letrozole Breast Cancer0.491109
estrogen receptor0.488845
advanced hormone-sensitive breast0.480069
receptor–positive breast cancer0.52072
breast cancer0.988243
Breast Cancer Trialists0.51995
adjuvant tamoxifen0.489054
tamoxifen treatment0.48115
hormone receptor–positive breast0.534822
et al0.566786
advanced breast cancer0.554835
CLICK HERE
2020 National Cancer Institute Html es Prevención del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud Sumario de información revisada por expertos sobre los factores que aumentarían el riesgo de presentar cáncer de cuello uterino y los enfoques que ayudarían a la prevención de esta enfermedad.
cervical intra-epithelial neoplasia0.302624
Obstet Gynecol0.303555
Lancet Infect Dis0.302739
vacuna qHPV0.302144
VPH vs0.303877
cervical carcinoma0.305011
cáncer invasor0.318393
González A0.303459
VPH oncógenos0.304066
American Cancer Society0.303348
case-control study0.30305
Costa Rica Vaccine0.302774
cervical neoplasia0.303702
Schiffman M0.30246
without cervical carcinoma0.302609
risk factors0.303566
collaborative reanalysis0.305986
International Collaboration0.302415
Estados Unidos0.303742
vacuna 9vHPV0.303595
cancer in0.308272
Natl Cancer Inst0.304144
cervical cancer0.371053
vacuna vph0.305378
North American multicohort0.3021
9-valent hpv vaccine0.303034
VPH Población Estimación0.304092
Quadrivalent HPV Vaccination0.302755
human papillomavirus0.353991
vacuna nanovalente vlp0.302596
risk among hiv-infected0.30327
Bosch FX0.30227
Castle PE0.302445
Muñoz N0.303856
Costa Rica0.303541
collaboration prospective study0.303065
Immune Defic Syndr0.302422
multicohort collaboration prospective0.302636
Adverse Pregnancy Outcomes0.302449
Acquir Immune Defic0.302422
epidemiological studies0.313912
with cervical carcinoma0.302983
vacuna vph-16 l10.302668
cervical intraepithelial neoplasia0.304671
cuello uterino0.985138
American multicohort collaboration0.302442
Cancer In young0.302413
vacuna bivalente tipo0.302487
cancer risk0.305603
CLICK HERE
2022 National Cancer Institute Html es Exámenes de detección del cáncer de cuello uterino (PDQ®)–Versión para pacientes Sumario de información revisada por expertos sobre los exámenes que se utilizan para detectar el cáncer de cuello uterino.
siguientes grupos0.30039
PDQ Exámenes0.300773
Physician Data Query0.301635
libre uso0.300195
cuello uterino0.99515
prevención revisa0.300275
largo plazo0.300411
principal factor0.302387
información ayuda0.300455
National Cancer Institute0.300349
siguientes riesgos0.300249
siguientes sumarios0.301285
Instituto Nacional0.300751
CLICK HERE
2033 National Cancer Institute Html es Prevención del cáncer de próstata (PDQ®)–Versión para profesionales de salud Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad.
Thompson IM0.314327
accessed july0.302228
results from0.303565
Connolly JM0.303382
Prostate Cancer Events0.317969
habitantes hombres0.302425
Cancer Statistics Review0.317133
Ross RK0.305958
Sin embargo0.309562
grasas animales0.30255
American Cancer Society0.316034
dietary fat0.303757
tumores gleason0.303142
productos lácteos0.302873
Cancer Rates0.308415
EI aumento0.303513
EI riesgo0.304572
Prostate specific0.303323
Estados Unidos0.302842
Natl Cancer Inst0.462208
Gleason DF0.304482
cancer prevention trial0.348935
menor riesgo0.303815
Prostate Cáncer Prevention0.30803
SEER Cancer Statistics0.317438
investigation into cancer0.307885
Bernstein L0.303522
prostate cancer prevention0.326581
Prostate Prevention Trial0.304615
Tangen CM0.304256
Kristal AR0.303247
EI Prostate Cancer0.311391
United States0.314913
Prostate Cancer Clinical0.31207
Cancer Facts0.309636
Kolonel LN0.303682
prostate lncap tumors0.303282
among japanese0.304198
Nutr Cancer0.308752
National Cancer Institute0.326849
Epidemiol Biomarkers Prev0.307319
dutasterida vs0.303715
antecedentes familiares0.303019
fatty acids0.303826
Prostate Cancer Survey0.310986
Prostate visualization studies0.303528
grasas alimenticias0.316785
prostate cancer0.996017
Rose DP0.305512
CLICK HERE
2049 National Cancer Institute Html es Trasplantes de células madre formadoras de sangre Hoja informativa que explica los procedimientos, paso a paso, del trasplante de médula ósea y del trasplante de células madre de sangre periférica, así como sus riesgos y beneficios.
células madre0.995824
efecto gvt0.300369
trasplante autólogo0.304497
PBSCT alogénicos0.300755
llamadas antígenos0.300572
frecuencia células madre0.306001
bone marrow transplantation0.300883
raros casos0.300403
Sin embargo0.307734
catéter venoso central0.300806
Programa Nacional0.300971
llamadas células madre0.30624
largo plazo0.300324
causa disminución0.300351
seguro médico0.300814
cubre be0.300325
paciente transfusiones0.301172
HLA compatibles mejora0.301344
idéntico.  sin embargo0.300876
antígenos hla0.303269
stem cell transplantation0.300928
programa be0.300461
posibles efectos0.301054
linfocitos t". 0.3004
atacan.  más0.300461
GVHD aguda0.300451
corto plazo0.30031
sangre.  solo0.300435
usa dosis0.301797
tipo hla0.300841
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.